Figure 6 | Scientific Reports

Figure 6

From: Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma

Figure 6

Combination treatment of etoposide with anti-CCL2 Ab decreases tumor burden in NOD-SCID gamma mice (NSG) injected with neuroblastoma (CHLA-255-Fluc and NGP-Fluc) in a minimal residual disease mouse model of neuroblastoma. (A) Following tumor resection of CHLA-255-Fluc orthotopic xenografts, mice were divided into four treatment groups (control, anti-CCL2 antibody alone, etoposide alone, and combination of etoposide and anti-CCL2 antibody) and underwent weekly bioluminescent imaging to measure tumor burden over time. (B) Combination therapy of anti-CCL2 Ab and etoposide led to significantly decreased tumor burden compared to untreated control. (C) Repeat experiment utilizing the NGP-Fluc neuroblastoma cell line. (D) Combination therapy of anti-CCL2 Ab and etoposide demonstrated decreased tumor burden compared to control. Interval regression was performed and line graphs with errors bars represent mean ± SD.

Back to article page